December 3, 2013

Sanofi Announces New Phase 3 Results for Investigational New Insulin U300

EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus®

EDITION III, IV and JP I studies meet primary endpoint

 

Sanofi Announces New Phase 3 Results for Investigational New Insulin U300
EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus®

Paris, France – December 3, 2013 – Sanofi announced the full results from the EDITION II study showing that investigational new insulin U300 demonstrated similar blood sugar control with 23% fewer patients experiencing night-time low blood sugar compared with Lantus® (insulin glargine [rDNA origin] injection). These results were presented today at the International Diabetes Federation 2013 World Diabetes Congress in Melbourne, Australia. The full EDITION II results are consistent with those from EDITION I.1 Both studies were conducted in people with type 2 diabetes already using basal insulin (with mealtime insulin or oral medication).